GIORNATE DIABETOLOGICHE d e l l ’ E M I L I A - R O M A G N A : RENE CUORE E DIABETE 1 EDIZIONE 1a Left Ventricular dysfunction in T2 Diabetes (the DYDA Study) Marco Comaschi DYDA p , multicenter,, epidemiological p g study y Prospective, Primary objectives To evaluate the prevalence of left ventricular dysfunction (LVD) (LVD), diastolic or systolic in patients with type II diabetes mellitus in the absence of clinical signs/symptoms of cardiac abnormalities To identify the predictors of LVD LVD = Left Ventricular Dysfunction (systolic and/or diastolic) Systolic dysfunction (EF ≤50% and/or MFS ≤15%) Diastolic dysfunction (deceleration time ≤140 or 1.5<E/A<0.75) Secondary objectives • To evaluate the incidence of LVD, either systolic or di t li att 2 year follow-up diastolic, f ll i patients in ti t without ith t LVD att study entry • To evaluate l the h incidence i id andd the h characteristics h i i of ECG abnormalities at 2 year follow-up in patients with a normall ECG at study d entry • To evaluate the 2-year incidence of a combined outcome measure of all-cause death and hospitalizations for CV causes • To identify the predictors of CV events (all-cause death or CV hospitalizations) p ) STUDY POPULATION Inclusion criteria • Type 2 diabetes • No symptoms and/or clinical signs of cardiac diseases • Age > 45 years Note: Left ventricular hypertrophy was not considered id d as an exclusion l i criteria it i 970 patients enrolled p 10 patients with protocol violation 960 yp population p study Baseline characteristics Total population (n 960) (n. Age (yrs), median IQR [25%-75%] Females % Females, BMI (kg/m2), median IQR [25%-75%] 61 [56-67] 38 1 38.1 28.0 [25.5-31.2] g ((BMI 25 - <30), ), % Overweight 43.9 Obese (BMI ≥30), % pharmacologically treated % 34.7 0.8 HR (bpm), median IQR [25%-75%] 72 [66-80] SBP (mmHg), median IQR [25%-75%] 137 [130-145] DBP (mmHg), ( H ) median di IQR [25%-75%] [25% 75%] 80 [75 [75-85] 85] Waist circonference (cm), median IQR [25%-75%] Males, median IQR [25% [25%-75%] 75%] Females, median IQR [25%-75%] 99 [92-106] 100 [94-107] [94 107] 98 [90-105] Waist circonference and BMI Waist circonference (cm) Median [25%-75%] Total population BMI <25 kg/m2 BMI [25-30) kg/m2 BMI ≥30 kg/m2 99 [92-106] 89 [83 [83-94] 94] 98 [93-102] 108 [102-115] Males BMI <25 kg/m2 BMI [[25-30)) kg/m g 2 BMI ≥30 kg/m2 100 [94-107] 90 [86-95] 98 [[94-102]] 110 [105-116] BMI <25 kg/m k / 2 BMI [25-30) kg/m2 BMI ≥30 kg/m2 98 [90-105] 85 [80 [80-92] 92] 96 [89-102] 104 [99-112] Females Pharmacological treatment % Betablockers 11.5 ACE-inhibitors 31.5 ARBs 25.9 Diuretics 22.3 Ald Aldosterone bl k blockers 09 0.9 CCBs 17.2 ASA 26.9 Other antiplatelets 4.3 Statins 37.9 n-3 PUFA 3.7 Other antihypertensive agents 5.9 Bronchodilators 17 1.7 FANS 1.3 Allopurinol 2.7 Antidepressants 1.6 Benzodiazepine 2.0 DYDA: Total population (n. 970) LVD = Left Ventricular Dysfunction (systolic and/or diastolic) DYDA: Patients with ventricular function measurable (n. (n 751) LVD = Left Ventricular Dysfunction (systolic and/or diastolic) Systolic dysfunction (EF ≤50% and/or MFS ≤15%) Diastolic dysfunction (deceleration time ≤140 or 1.5<E/A<0.75) Independent predictors of LV dysfunction (n 450/751 pts) (n. Model adjusted for clinical li i l variables i bl andd laboratory l b examinations i i and pharmacological treatments and ECG Age (continuous (contin o s variable) ariable) HbA1c (continuous variable) Ti l Triglycerides id (continuous ( i variable) i bl ) Metformin Glitazones P wave (V1) ≥40msec Doxazosine OR 1 05 1.05 1.26 1 003 1.003 1.63 0.53 1.51 2.24 95%CI 1 02 1 07 1.02-1.07 1.08-1.48 1 001 1 005 1.001-1.005 1.11-2.39 0.30-0.94 1.02-2.22 1.03-4.90 Published papers Inappropriately high left ventricular mass in patients with type 2 diabetes mellitus and no overt cardiac disease. disease The DYDA study. study Cioffi G, Faggiano P, Lucci D, Di Lenarda A, Mureddu GF, Tarantini L, Verdecchia P, Comaschi M, Giorda CB, Velussi M, Chinali M, Latini R, Masson S, De Simone G; DYDA Investigators. Investigators J Hypertens. 2011 Oct;29(10):1994-2003. Analysis of midwall shortening reveals high prevalence of left ventricular myocardial dysfunction in patients with diabetes mellitus: the DYDA study. Cioffi G, Giorda CB, Chinali M, Di Lenarda A, Faggiano P, Lucci D, Maggioni AP, Masson S,, Mureddu GF,, Tarantini L,, Velussi M,, Comaschi M. Eur J Cardiovasc Prev Rehabil. 2011 Jul 28. Predictors of early-stage y g left ventricular dysfunction y in type yp 2 diabetes: results of DYDA study. Giorda CB, Cioffi G, de Simone G, Di Lenarda A, Faggiano P, Latini R, Lucci D, Maggioni AP, Tarantini L, Velussi M, Verdecchia P, Comaschi M. Eur J Cardiovasc Prev Rehabil. 2011 Feb 22. Paper submitted • NT-proBNP, hsCRP and microalbuminuria i i i in patients with type-2 diabetes mellitus without overt cardiac disease : data from the Left ventricular Dysfunction In DiAbetes (DYDA) study. – Solo la MAU ha un sicuro significato g di predittività – NT-proBNP p e hsCRP raggiungono gg g la significatività g all’analisi univariata, ma la perdono nella multivariata Patient disposition 970 pts enrolled excluded Baseline 10 pts with protocol violation 960 pts Study population ECG 914 pts with ECG available 878 pts with LVH evaluable 2 years follow up follow-up ECHO 833 pts t with ith ECHO available il bl 751 pts with LVD measurable 805 pts with diastolic dysfunction measurable 705 ppts with sistolic dysfunction y measurable 3pts lost to follow-up - 2 consent withdrawals Median follow-up 746 days, days mean 743±99 CLINICAL DATA ECG 957pts with data on events available 911 pts with clinical visit 844 pts with ECG available 800 pts with LVH evaluable LVH=left ventricula hypertrophy LVD=left ventricular dysfunction ECHO 727 pts with ECHO available 589 pts with LVD measurable 696 pts with diastolic dysfunction measurable 513 pts with sistolic dysfunction measurable Follow-up: Clinical events Death n. (%) All All-cause d h death 15 (1 (1.6%) 6%) CV death 3 (0.3%) Non CV death 11 (1 (1.2%) 2%) Unknown cause of death 1 (0.1%) Hospitalizations n. All-cause hospitalizations 181 CV hospitalizations 48 Hospitalizations for non CV cause 133 CV = cardiovascular Follow-up: Patients with clinical events n. (%) All-cause death 15 (1.6%) CV death 3 (0.3%) Non CV death 11 (1.2%) Unknown k cause off death d h 1 (0.1%) (0 1%) P i Patients admitted d i d Patients admitted for a CV reason 139 (14 (14.5%) 5%) 43 (4.5%) Patients admitted for a non CV reason 104 (10 (10.8%) 8%) All-cause All cause death or hospitalization 142 (14 (14.8%) 8%) All-cause death or CV hospitalization p admission for CV cause CV death or hospital Non CV death or hospital admission for non CV cause CV = cardiovascular 53 (5.5%) 44 ((4.6)) 107 (11.2%) Independent predictors of all-cause death or hospitalization 2,01 Repaglinide (yes vs no) 3,49 Claudicatio C aud cat o (yes vs no) 1,39 LDL (continuous variable) (134 vs 93 mg/dL) HDL (continuous variable) ((57.0 vs 42.5 mg/dL) g ) HbA1c (continuous variable) (7.6 vs 6.0 %) Age (continuous variable) (67 vs 56 years) 0,76 1,30 1,41 0,00 1,00 2,00 3,00 4,00 5,00 6,00 7,00 8,00 Left Ventricular Dysfunction 960 pts study population excluded 940 pts analyzed 20 pts with major coronary events (admission for: HF, MI, unstable angina, revascularization, atrial tachyarrhythmias) Systolic/Diastolic Systolic Diastolic Baseline/2 years (699 pts) Baseline/2 years (529 (5 9 pts) Baseline/2 years (696 pts) 616 (88.1%) 338 (63.9%) 463 (66.5%) Independent predictors of LVD 1,28 HR (continuous variable) (80 vs 68 bpm) 1,47 HbA1c (continuous variable) ((7.6 vs 6.0 %) 2 15 2,15 Age (continuous variable) A (67 vs 56 years) 0,00 1,00 2,00 3,00 4,00 Independent predictors of diastolic dysfunction Age (continuous variable) (67 vs 56 years)) DBP (continuous variable) (90 vs 78 mmHg) HR (continuous variable) (80 vs 68 bpm) HbA1c (continuous variable) (7.6 vs 6.0 %) OR 95%CI p 2.45 1.86-3.23 <.0001 2.29 1.41-3.72 0.0072 1.23 1.03-1.47 0.0245 1.25 1.01-1.54 0.0382 Independent predictors of systolic dysfunction Waist circonference ((continuous variable)) (106 vs 92 cm) OR 95%CI p 1 39 1.39 1 05 1 84 1.05-1.84 0 0196 0.0196 Left Ventricular Dysfunction Systolic Dysfunction (388 pts) no (EF≤50% and/or MFS≤15%) no 83 90 (18.3%) (19.8%) Baseliine Baselline LVD (454 pts) t ) no yes 55 226 yes (12.1%) (49.8%) B Baselin ne 24 months 191 66 no (49.2%) (17.0%) 54 77 yes (13 9%) (19 (13.9%) (19.9%) 9%) no yes 233 126 no ((40.7%)) ((22.0%)) yes yes 92 121 (16.1%) (21.2%) 24 months 24 months Di t li Dysfunction D f ti Diastolic (572 pts) Conclusions 1 Conclusions-1 • In patients with type II diabetes mellitus without clinical signs or symptoms of cardiac abnormalities, b li i LVD, LVD either i h systolic li or diastolic di li detected at echo, is a frequent finding • All-cause death or hospitalization occur at 2 year follow-up in nearly 15% of the cases, cases being the great majority of them of non cardiac reason Conclusions-2 • Older age, high LDL, low HDL, high Hb1Ac, symptomatic peripheral arterial disease and treatment with repaglinide were independently associated with all-cause death or hospitalizations • Older age, high Hb1Ac and high HR independently predict the presence of LVD • The Th same variables i bl plus l high hi h DBP independently i d d tl predict diastolic dysfunction, while systolic dysfunction was independently i d d l predicted di d by b large l waist i circumference only Take home messages g • Che cosa davvero possiamo portarci a casa dei risultati del DYDA? – È uno studio di “osservazionale”, “ i l ” e come tale l non è in grado di proporre messaggi di comportamento clinico li i – Tuttavia, i risultati sono molto significativi, e indicano con chiarezza che la fisiopatologia del diabete di tipo 2, e la gestione del controllo metabolico, hanno una rilevanza ancora superiore all’attesa Take home messages • Le implicazioni i li i i principali i i li sono proprio i di ordine di fisiopatologico, e indicano nella resistenza all’insulina ll’i li la l causa del d l danno d miocardico i di • Studi di intervento specifici, basati sulla valutazione della popolazione del DYDA in risposta a particolari trattamenti del diabete possono aprire i orizzonti i i importanti i i • In particolare, alcuni riscontri sulle terapie che si basano sull’asse incretinico possono indirizzare gli studi di intervento Participating centres Torino (Aurora Grassi, Grassi Alfredo Pizzuti); Chieri (Tecla Marchese, Marchese Lidia M.T. M T Brero); Cuneo (Gianpaolo Magro, Franca Margaria); San Paolo, Milano (Anna Veronelli, Francesca Carletti); San Raffaele, Milano (Piermarco Piatti, Eustachio Agricola); Bergamo (Alessandro R. Dodesini, Michele Senni); Brescia, (Liliana Rocca, Pompilio Faggiano); Rozzano (Luca Genovese); Sesto San Giovanni (Ezio Faglia, Roberto Mattioli); Mirano, (Loris Bortolato, Albino Zanocco); Osp. Riuniti, Trieste, (Maurizio Fonda, Bruno Pinamonti); Aurisina, (Mario Velussi, Bruno Pinamonti); ); Azienda Servizi,, Trieste ((Elena Manca,, Bruno Pinamonti); ); Sanremo,, ((Roberto Sturaro, Silvia Ubaldi); San Martino, Genova (Alberto De Micheli, Roberto Delfino); Villa Scassi, Genova (Alberto Aglialoro, Ornella Magaja); Arenzano (Paola Ponzani, Alberto Camerini); DIMI - DISEM, Genova (Davide Maggi, Paolo Spallarossa); Montecchio Emilia (Valeria Manicardi, Elisabetta Catellani); Scandiano (Elisa Monzali, Gian Paolo Gambarati); Bologna (Alessandra Sforza, Riccardo Rambaldi); Rimini (Mario Parenti, Silvia Amati); Prato (Adolfo Arcangeli, Toni Badia); Nuovo San Giovanni di Dio, Firenze (Anna Leopardi, Antonio Sulla); Careggi, Firenze (Gianluca Bardini, Mauro Lenuzza); Grosseto (Gigliola Sabbatini, Francesca Cesareo); Perugia (Giampaolo Reboldi, Paolo Biagioli); Terni (Augusto Travaglini, Daniella Bovelli); Ancona (Massimo Boemi, Roberto Mocchegiani); San Benedetto Del Tronto (Gi (Giacomo V Vespasiani, i i Guglielmo G li l D Curtis); De C i ) Marino M i (Patrizio (P i i Tatti, T i Paolo P l Midi); Midi) Napoli N li (Sandro (S d Gentile, Domenico Cozzolino); San Giovanni Rotondo (Simonetta Bacci, Aldo Russo); Catania (Rosa Maria Motta, Giuseppe Leonardi); Iglesias (Angelo Corda, Luisa Pitzalis); Cagliari (L i C b i Cristiana C i ti M t ld ) Oristano Oit (Gi f M d Sergio S i Mariano M i M hi) (Luciano Carboni, Montaldo); (Gianfranco Madau, Marchi) DYDA Steering Committee Marco Comaschi (Chairman), Andrea Di Lenarda (Co-Chairman) Pompilio Faggiano, Carlo Giorda, Luigi Tarantini, Mario Velussi Working Group of the ecocardiographic substudy on hypertension and left ventricular dysfunction Pompilio Faggiano gg ((Coordinator), ) Gianni Cioffi, Giovanni de Simone, Gianfrancesco Mureddu, Paolo Verdecchia Executive Committee M Marco Comaschi, C hi Andrea A d Di Lenarda, L d Aldo Ald Pi Pietro t M Maggioni i i Biomakers core laboratory Serge Masson, Roberto Latini (Istituto Mario Negri, Milano), Tarcisio Vago (Ospedale Luigi Sacco, Milano) ECG core laboratory Fabio Angeli, Giovanni Mazzotta, Salvatore Repaci ECO core laboratory Gi i De D Simone, Si Il i Botta, B tt Giusy Gi C l M ll Chinali, Chi li Daniela D i l Giovanni Ilaria Casalnuovo, Marcello Girfoglio Thank you for your kind attention